Sarepta Therapeutics (NASDAQ: SRPT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.270 | -0.560 | 0.7100 | ||||
REV | 206.440M | 210.830M | 4.390M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Sarepta Therapeutics (NASDAQ: SRPT) through any online brokerage.
Other companies in Sarepta Therapeutics’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Ionis Pharmaceuticals (NASDAQ:IONS) and Amgen (NASDAQ:AMGN).
The latest price target for Sarepta Therapeutics (NASDAQ: SRPT) was reported by Cantor Fitzgerald on Friday, June 24, 2022. The analyst firm set a price target for 128.00 expecting SRPT to rise to within 12 months (a possible 69.07% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $75.71 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Sarepta Therapeutics.
Sarepta Therapeutics’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Sarepta Therapeutics.
Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.